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Summary: Clinicians should be able to provide the patient with Alzheimer 
disease (AD) and the family with an accurate prediction of what to expect, 
but the variability in the rate of disease progression precludes this. In several 
previous studies, specific clinical signs such as muscular rigidity, myoclonus, 
and hallucinations or delusions were associated with rapid progression to a 
more severe stage of dementia or death. The "Predictors Study," a longi-
tudinal study at three independent sites, was designed to develop a predictor 
model of the natural history of Alzheimer disease. The study was conducted 
at three study sites, New York, Baltimore, and Boston in a cohort of 224 
patients with early probable AD. This article describes the design and im-
plementation of the Predictors Study, and compares features of the study 
cohort at baseline across sites. Patients were all at the mild stage of disease 
at entry and were relatively comparable across sites. Extrapyramidal signs 
and delusions were common, but myoclonus was rarely obsetved. Key Words: 
Multicenter study-Predictors of disease course-Dementia. 
The rate that Alzheimer c;lisease (AD) progresses is variable (Mayeux et al., 
1985; Stem et al., 1987a). We cannot presently predict how long it will be until 
a patient reaches critical mi.estones in disease progression such as the inability 
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to maintain him or herself without assistance-information that would be useful 
to both patient and family. The inherent variability in the course of the disease 
also makes it difficult to evaluate the results of clinical interventions such as 
drug trials. We initiated a multicenter study to develop reliable methods for 
estimating the expected length of time until a specific disease outcome occurs, 
based on information obtained by a clinician early in the course of the disease. 
Measurable findings that can help predict disease outcomes have been termed 
predictors (Wasson et al., 1985). The predictors must be relevant and clearly 
defined clinical features of the disease, based on easily reproducible observations. 
Finally, predictors must not be part of the diagnostic criteria for the illness 
investigated. If, for example, the criteria for an outcome require the presence of 
a predictor variable, the investigator might conclude that the finding is powerful. 
This is why we chose to use clinical predictors such as extrapyramidal signs 
(EPS), as opposed to definitive features of dementia such as memory impairment, 
as predictors. 
An outcome used as the object of prediction must meet several criteria: (a) It 
must represent a clearly defined event or consequence of the illness that is free 
of ascertainment bias; (b) it must be relatively easy to establish, based on ob-
servations or reports of informants; (c) it must be distinct from diagnostic criteria 
and from the predictors; ( d) it should reflect disease severity and progression in 
the majority of cases. 
Variability of disease progression may reflect phenotypic heterogeneity, phe-
nocopies, or the results of both genetic and environmental factors. Although this 
is speculative, clear elaboration of predictors of varying disease course would 
be a first step toward approaching this issue. 
This report describes the design and implementation of the "Predictors Study," 
a multicenter study to identify prediction of decline in AD, and describes baseline 
data from a cohort recruited across three clinical research sites. 
METHODS 
Overview 
Three centers participated in the Predictors Study, Columbia University (CU), 
Johns Hopkins University School of Medicine (JH), and Massachusetts General 
Hospital (MGH). 
Each center recruited patients who met diagnostic criteria for probable Alz-
heimer disease (pAD) (McKhann et al., 1984) and were in the early stage of the 
disease. After determining that inclusion and exclusion criteria were satisfied, 
historical and demographic information were collected. Neurological, neuro-
psychological, psychiatric, and functional assessments were performed at the 
baseline visit and repeated at 6-month intervals. In addition, patients' living 
situation and medical status were monitored. 
The primary predictors chosen for this study were the presence of extrapyr-
amidal signs, myoclonus, and/or psychotic symptoms, based on our previous 
experience with. a smaller cohort of patients with pAD (Mayeux et al., 1985; 
Stern et al., 1987a; Stern et al., 1990). Additional potential predictive signs, 
Alzheimer Disease and Associated Disorders, Vol. 7, No. 1, 1993 
PREDICTORS OF DISEASE COURSE IN ALZHEIMER'S : I 5 
based in part on other reports, were presence or absence of history of dementia 
in first degree relatives, slowed dominant posterior rhythm on EEG, presumed 
stroke without clinical correlates, and age at onset of symptoms. 
Two types of outcomes were utilized: (a) specific disease milestones, such as 
reaching a specific score on a mental status examination, entry into a nursing 
home, or death, have dichotomous variables for approaches such as life table 
analyses, and (b) scores on rating scales of cognitive and functional ability, as 
descriptors of disease severity for other parametric analyses. 
Subjects 
A total of 224 patients (91 from CU, 76 from JH, and 57 from MGH) gave 
informed consent and underwent baseline evaluation. 
Methods of Recrnitment 
At the CU site, patients were recruited from the Memory Disorders Center 
and from doctors' private offices through the Alzheimer Disease Research Center. 
Each consecutive patient who met inclusion and exclusion criteria was enrolled, 
with the exception of those who would not provide informed consent or who 
lived too far from the hospital to maintain regular follow-up. 
At the JH site, 47 patients were recruited from the dementia Research Center 
at the JH Hospital, Department of Psychiatry, 21 were referred from private 
physicians, seven were recruited from the Department of Neurology at JH Hospi-
tal and one was referred from the Psychogeriatric Center at JH Hospital. All 
subjects were outpatients. 
For the MGH site, 14 patients were recruited from the Hebrew Rehabilitation 
Center for the Aged in Boston, a chronic long-term care facility, and eight 
patients were entering a physostigmine study. The remaining patients were re-
cruited through the Geriatric Neurobehavioral Center at MGH, an outpatient 
service, in the same fashion as at CU. 
Inclusion Criteria 
Each patient was required to meet NINCDS-ADRDA criteria for pAD (McKhann 
et al., 1984). Intellectual impairment was documented by neuropsychological 
testing using the standard clinical batteries of each institution. Although actual 
test batteries differed somewhat at each center, they all included tests of memory, 
orientation, abstract reasoning, language, attention, and construction. 
To ensure that severity of dementia was mild at study entry, all patients were 
required to have a modified Mini-Mental State Examination (mMMSE) (Mayeux 
et al., 1981) score of 30 or above (corresponding to approximately 16 on the 
standard Mini-Mental, Folstein et al., 1975). 
Each patient was required to have at least one family member, close friend, 
or health aid who consented to serve as patient advocate. All patients were 
required to speak English, either as a primary language or as a fluent second 
language. Because the present cohort formed the basis of a prospective, longi-
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tudinal study, patients who indicated that they would not return to these centers 
on a regular basis (e.g. patients who came for a single consultation) were not 
included. 
Patients with "lacunae" or small "vascular" lesions that were clinically and/ 
or historically silent and were judged to be less than 2 cm in diameter were 
included. Diffuse symmetric periventricular lesions, such as those consistent with 
small-vessel ischemic change or infarcts, or indicative of cerebrospinal fluid 
(CSF) absorption abnormalities, were not grounds for exclusion. However, pa-
tients with cortical lesions of any size or location, or with focal cortical atrophy 
secondary to an infarct, were excluded. 
To ensure accurate initial assessment of psychotic symptoms, all patients were 
required to be maintained off of antipsychotic medications for at least 1 month 
before their initial evaluation. 
Exclusion Criteria 
We excluded patients with a history or current clinical evidence of schizo-
phrenia or schizoaffective disorder before onset of intellectual decline; any elec-
troconvulsive (ECT) treatment sessions within 2 years of recruitment, or 10 or 
more ECT treatment sessions at any time; alcohol abuse/dependency [DSM-
III-R (1987) criteria] at the time of recruitment; or clinical or historical evidence 
of stroke. 
Procedures 
Data Collected at Initial Evaluation 
Historical and demographic data. Standardized questionnaires were used for 
age, education, occupation and employment history, family history of dementia 
or other diseases in first degree relatives, and current medication use. Medical 
history was also reviewed and coded, with detailed sections for hypertension, 
diabetes, and myocardial infarction. Specific queries for the presence of thyroid 
disease, lymphoproliferative disorders, head injury, and Down syndrome were 
made. The Hachinski Ischemia Scale (Hachinski et al., 1975) was administered 
to assess risk of vascular disease. 
Neurological examination. At the initial visit, a standardized medical and 
neurological examination was performed. Neurological examinations were re-
peated on follow-up visits if a change in the patient's medical condition (e.g., 
hospitalization or new medical diagnosis) had occurred in the intervening period. 
Presenting features of dementia. The patient's primary and secondary disease 
manifestations, as discerned by the examining physician, were recorded, selected 
from the following list of clinical features: memory change, performance change, 
language change, disorientation, personality change, depressed mood, behavior 
change, and psychosis. 
Onset dating and features. Based on the interview of the patient and inform-
ants, the physician estimated disease duration. Disease onset was also separately 
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estimated utilizing a reliable, standardized interview technique (Sano et al., 1987) 
that asks the informant to date both the onset of clinical features and the latest 
time they were absent, relative to concrete time markers such as holidays or 
birthdays. 
Brain imaging. All patients underwent a computed tomography (Cf) or magnetic 
resonance imaging (MRI) scan as part of their diagnostic evaluation, and the 
radiologists' reports were utilized to evaluate the presence of an exclusion cri-
terion (e.g., cortical infarcts). 
All available scans were reviewed and rated by a single neuroradiologist at 
the CU site (JB). Since patients with clinically silent, small subcortical infarcts 
were included in the study, the presence, frequency, and location of these infarcts 
were recorded. Ratings of atrophy were made in a format similar to that utilized 
by the "professional judgment of atrophy" item in the CERAD protocol (Davis 
et al., 1989), taking the patients' age into account. 
Subcortical white matter lesions or infarcts were noted, and rated along the 
following scale: none, single (;;::3 mm, :s2 cm), few ( <5 or <2 confluent), 
multiple (;;::5 or 2 confluent), diffuse (many confluent). Lesion location was noted 
and assigned to standardized categories. The presence or absence of frontal or 
parietal periventricular "'caps" (areas of increased signal seen at the poles of the 
ventricles) was rated in each hemisphere. For MR scans, periventricular "halos" 
(smooth lines of increased signal at the periventricular margin) were rated as 
absent, thin (normal), or thick (abnormal). 
EEG. Patient EEG reports were extracted in a checklist format. Items included 
slowed dominant rhythm, focal slowing, intermittent rhythmic slowing/8 wave 
activity, and other slowing and epileptiform activity (focal or generalized). 
Psychiatric history. Information concerning past hospitalizations and medi-
cation for psychiatric problems was elicited. If a history of depression was iden-
tified, the kind of treatment, if any, was recorded. 
Family history of dementia. A list of first-degree relatives of each patient 
was compiled, along with age at, and cause of, death. Also recorded was whether 
each family member has or had dementia, based on the report of the informants. 
Data Collected at Initial and Follow-up Visits 
The following assessments were completed at the initial and at all subsequent 
follow-up evaluations. 
Medication. Since specific medications might influence evaluated perform-
ance, current medications at the time of assessment, along with their indication 
and efficacy, were recorded on a standardized checklist form. Amount and form 
of alcohol consumed was also recorded. 
Seizures. The presence and frequency of seizures, whether or not suggested 
by EEG abnormality, were recorded. 
Any repeat imaging or EEG studies were noted and their results recorded. 
Medical and neurological examinations were repeated if any significant med-
ical event occurred in the 6 months before a visit. 
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Assessment of Potential Predictive Signs 
The following assessments occurred at the initial and at each subsequent 6-
month visit. 
Extrapyramidal signs rating. Selected items from the Unified Parkinson's 
Disease Rating Scale (Stern, 1983) were used, comprising ratings of voice, 
facial immobility, resting tremor, rigidity (neck and each limb), brady/hy-
pokinesia, posture and gait [see Richards et al. (1991) for complete form]. 
Severity of each sign was rated as either absent (0), slight (1), mild-moderate 
(2), marked (3), or severe (4). Signs were coded as either idiopathic, induced 
by current neuroleptic medication, or possibly induced by previous neuroleptic 
medication. The presence of chorea, myoclonus, and other dyskinesias was 
also recorded. Interrater reliability of this examination has been established 
(Richards et al., 1991). 
Psychosis and behavioral changes. A semistructured interview, the Columbia 
University Scale for Psychopathology in Alzheimer's Disease (CUSPAD) (De-
venand et al., 1992) elicited information about symptoms of delusions, halluci-
nations, illusions, depressed mood, and other specific behavioral signs occurring 
during the month before assessment. Specific delusions queried included paranoid 
delusions, delusions of abandonment, somatic delusions, and misidentifications. 
The CUSP AD assessed delusion severity based on frequency and the readiness 
of the patient to accept the truth if corrected. Only if the patient was resistant to 
accepting correction was a delusion considered to meet DSM-111-R (1987) di-
agnostic criteria. Hallucinations and illusions, if present, were rated as either 
vague or clear. Behavioral problems, including wandering, verbal outbursts, 
physical threats and/or violence, agitation or restlessness, and nighttime confu-
sion were rated as present or absent. The presence of depressed mood was scored 
on a 5-point severity scale. 
Depression. In order to supplement the CUSP AD rating of depressive symptoms, 
the Hamilton Depression Scale (Hamilton, 1960) was administered jointly (where 
possible) to the patient and the informant. An interview format was used to 
standardize administration (Williams, 1988). 
Assessment of Disease Outcomes 
Cognitive assessment. Intellectual function was examined using the mMMSE 
(Mayeux et al., 1981). This is based on the standard Mini-Mental State Exam-
ination (Folstein et al., 1975) and includes the Wechsler Adult Intelligence Scale 
Digit Span subtest (Wechsler, 1955), and additional attention/calculation, general 
knowledge, language, and construction items. The maximum score on this test 
is 57. This is a valid and reliable instrument (Stern et al., 1987b) that is brief 
yet informative. Formal instructions and guides for its use have been developed. 
The mMMS yields subscores that are descriptive of specific intellectual functions: 
orientation, registration, recall, digit span, attention, naming, language, and con-
struction. We consider an mMMS score of 15, representative of moderate to 
severe pAD, as a specific end-point for prediction. 
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After mMMSE administration, the examiner noted whether the patient was 
mute or uncooperative, since this can affect interpretation of the test. At baseline 
testing, no patient was rated in these categories. 
Functional assessment. Functional capacity was rated using the Blessed 
Dementia Rating Scale (Part 1) (BDRS) (Blessed et al., 1968). The reliability 
and validity of this instrument have been established and it has proven to be 
useful in evaluating longitudinal changes in intellectual function. We have 
developed a structured interview to guide and standardize BDRS administra-
tion. We have also developed subscores for the BDRS based on factor analysis 
(Stern et al., 1990). These factors are cognitive, personality, apathy, and basic 
self-care. 
We consider a BDRS score of 10 as a specific end-point for prediction. We 
have also utilized specific scores as outcomes for the individual factors (Stern et 
al., 1990). 
Dependence rating. This scale (Stern et al., 1992) was adapted by investiga-
tors at Columbia from the work of Gurland et al. (1978), who assessed depend-
ence in community dwelling elders. Since a patient at home might receive care 
comparable to that at a skilled nursing facility, the intent of the scale was to 
document the extent of the patient's dependence, or need for the supervision and 
care of others. Part 1 of this scale assesses the amount of assistance required by 
patients. Items range from low level care such as supervision when outdoors to 
those indicative of a high level of dependence such as nasogastric feeding. A 
dependence level was derived from these items, ranging from 0, totally inde-
pendent, to 5, totally dependent. Part 2 recorded the rater's impression of the 
level of institutional or equivalent care received by the patient, irrespective of 
the patient's actual location. Categories included limited home care, adult home 
(a supervised setting with regular assistance in most activities), and health-related 
facility. 
Outcomes for the dependence scale include reaching a specific dependence 
stage and reaching a level of care equivalent to a health-related facility. 
Current status. At each 6-month evaluation, indicators of the patient's current 
status are recorded. These include work status, living situation (e.g., at home, 
in nursing home), or death (and cause of death). 
The Clinical Dementia Rating scale (CDR) (Hughes et al., 1982) was used to 
evaluate the patient at each measurement point to provide a global assessment 
of the severity of dementia. Dementia severity was rated mild (1), moderate (2), 
severe (3), profound (4), or terminal (5). This rating is based on all data collected 
and an interview with the patient and informant. 
Data Base Entry and Validation 
A data base was established at CU using SIR-DBMS software [SIR (USA), 
Deerfield, IL, U.S.A.] implemented on a network of microcomputers. Data was 
sent from all three sites to the study coordinator, who checked it for consistency 
and completeness before entry. 
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Study Personnel and Training 
Medical/neurological examination. All initial and follow-up neurological/ 
medical examinations were conducted by physicians (neurologists or psychia-
trists). All other inteiviews were conducted by staff trained at each site. All 
evaluations were supeivised by the principal investigator at that site. 
To ensure standardization of data collection methods, a meeting of the per-
sonnel of the three study sites was held before initiating the study to review all 
forms and procedures. Five patients and their informants (not in the current study) 
seived as practice subjects. 
Following this initial training session, visits of JH and MGR investigators to 
the CU site, as well as CU investigators to the other sites were arranged. Partic-
ular care was taken with training and monitoring of the rating of extrapyramidal 
signs, since this relies heavily on clinical judgment. A total of five additional 
training/review sessions were conducted at the three sites. In each case, a series 
of patients were jointly rated. CU investigators seived as the criterion raters, and 
differences in ratings between investigators were discussed and resolved. 
For the final two sessions, formal reliability trials were held, with one rater 
from each of the three sites independently rating the same 14 patients. Agreement 
for the presence or absence of EPS across the three raters was 100%. Consistency 
of the EPS ratings across raters, estimated with intraclass correlation (ICC), was 
excellent (ICC = 0.87). 
Similar additional sessions were held for other aspects of the study protocol, 
with emphasis on assessments that relied on clinical judgment to any degree. 
These included CUSPAD, onset rating, and the Hamilton Depression Scale. 
In addition to the formal sessions that were designed to enhance and monitor 
intersite reliability, the CU site seived as a clearing house for clarification of 
emergent issues in the application of the study protocol. Finally, data from all 
three sites was closely monitored for deviation from protocol. This included 
evaluation of written notes accompanying the ratings of most items on the as-
sessment forms. 
Statistical Analysis 
The primary analyses compared clinical and performance measures across the 
three study sites. x2 analyses were utilized for frequency data and analyses of 
variance or covariance for continuous variables. In all cases below, an a value 
of 0.05 or less was required for noting between group differences. 
RESULTS 
Demographic Features 
Two hundred twenty-four patients were recruited into the study. Approxi-
mately 345 additional patients with AD were screened but did not meet study 
entry criteria or refused to participate (120 at CU, 115 at JH, and 110 at MGR). 
Means and/or breakdowns for age, education, ethnic group, living situation, 
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marital status, and employment status are shown in Table 1, for the entire study 
and for each site separately. 
The proportion of men and women was evenly distributed across the study 
sites. There was no statistical difference in the educational level of the patients 
between the sties. However, a significant age difference across sites was found: 
Mean age of patients from MGH was notably higher than that for the other two 
sites. Almost all patients were white and were born in the United States. English 
was the predominant language spoken at home, although a small number of 
patients from the CU site spoke Spanish or another language at home. 
Seventeen patients were reported to be working full or part time at the time 
of the initial assessment; 26 were reported to have worked within the previous 
6 months. Approximately half of the patients with an employment history had 
retired under normal circumstances; 21 % stopped work early as a result of de-
mentia. 
Medical and Psychiatric History 
Approximately 30% of patients reported a history of hypertension and over 
20% of patients a history of hypercholesteremia (Table 2). A disproportionate 
number of these were from the JH site, as were patients with hypertri-
glyceridemia. Cardiac disease was defined as having at least one of the following: 
myocardial infarction, congestive heart failure, valvular heart disease, angina, 
atrial fibrillation or other cardiac arrhythmias. According to this definition, 56 
patients had at least one sign of cardiac disease; there was no significant differ-
ence in frequency across the sites. 
No other aspect of medical history differed significantly across sites. Fifty 
(23%) of the patients had been treated for depression at some time in the past; 
seven had had ECT, 42 had received medication for depression, and 19 under-
went therapy or counseling. 
Medical and Neurological Evaluation 
Presenting Complaints 
The most frequent presenting complaint was a memory deficit (81 % ), followed 
by difficulty with performing specific tasks. The distribution of presenting signs 
was comparable across sites (Table 3). 
Medical Examination 
Fifty-eight patients (28%) had at least one abnormal finding on medical eval-
uation; none was felt to contribute to the presentation of dementia. Fifty-eight 
patients were being treated for hypertension and eight met criteria for hyperten-
sion based on a blood pressure greater than 160/95. Frequency of treated hyper-
tension or hypertension at the time of examination did not differ across sites. 
Mean Hachinski score across all sites was 1.52 (SD = 1.35); scores did not 
differ significantly across sites. 
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TABLE 1. Demographic features of the pAD cohort 
Overall cu JH MGH 
n 224 91 76 57 
Sex 
M 91 (40.6%) 40 (44.0%) 31 (40.8%) 20 (35.1%) 
F 133 (59.4%) 51 (56.0%) 45 (59.2%) 37 (64.9%) 
Age (yr) 73.09 (8.74) 71.02 (8.04) 72.26 (7.82) 77.51 (9.52) 
Education (yr) 13.12 (3.65) 13.36 (3.62) 12.42 (4.14) 13.67 (2.81) 
Race/ethnicity: 
White 208 (92.9%) 83 (91.2%) 68 (89.5%) 57 (100%) 
Black 15 (6.7%) 7 (7.7%) 8 (10.5%) 0 
Hispanic 8 (3.4%) 6 (6.6%) 2 (2.6%) 0 
Born in U.S.A. 193 (86.5%) 71 (78.0%) 71 (94.7%) 51 (89.5%) 
Speak English at home 217 (96.9%) 84 (92.3%) 76 (100%) 57 (100%) 
Marital status 
Married 142 (63.4%) 65 (71.4%) 45 (59.2%) 32 (56.1%) 
Widowed 66 (29.5%) 18 (19.8%) 25 (32.9%) 23 (40.4%) 
Divorced/separated 14 (6.2%) 6 (6.6%) 6 (7.9%) 2 (3.6%) 
Work status: 
Working full or P(f 17 (7.6%) 10 (11.0%) 3 (3.9%) 4 (7.0%) 
Normal retirement 109 (48.7%) 35 (38.5%) 43 (56.6%) 31 (54.4%) 
Retired due to pAD 48 (21.4%) 28 (30.8%) 14 (18.4%) 6 (10.5%) 
Homemaker 24 (10.7%) 9 (9.9%) 4 (5.3%) 11 (19.3%) 
In this and all following tables, values in parentheses represent either percent or standard de-
viation. 
Neurological Examination 
Most features of the neurological examination were comparable across sites 
(Table 4). However, distributions differed significantly across sites for minor 
speech abnormalities and reflexes. In both cases, higher frequencies of abnor-
malities were noted in the JH group and probably represent differential sensitivity 
in endorsing these items. 
Medications 
Medications taken by patients at the time of recruitment are shown in Table 
5. In line with inclusion criteria, no patients were taking antipsychotic medica-
tions. Patients taking thyroid medications were not currently hypothyroid. Twenty 
patients were active participants in research drug trials for the treatment of AD; 
their drug/placebo status could not be determined at entry. Drug protocols include 
oral physostigmine, piracetam, acetyl-1-carnitine and tetrahydroaminoacridine. 
Laboratory Studies 
Diagnostic Imaging Studies 
All patients underwent either a CT or MRI study as part of their diagnostic 
workup; 150 had CT, 90 had MRI, and 16 had both. 
One hundred fifty-eight scans (55 MRI, 103 CT) were reviewed at the CU 
site by a single neuroradiologist (JB). Approximately 89% of the scans were 
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TABLE 2. Features of medical and psychiatric history in the cohort 
Overall CU JH MGH 
Medical History 
Hypertension 66 (29.7%) 25 (27.8%) 28 (37.3%) 13 (22.8%) 
Diabetes 13 (5.9%) 4 (4.4%) 6 (8.1%) 3 (5.5%) 
Cardiac risk factor 56 (25.5%) 20 (22.5%) 20 (27.0%) 16 (28.1%) 
Hypercholesterolemia 45 (20.7%) 15 (17.6%) 28 (37.3%) 2 (3.5%) 
Hypertriglyceridemia 10 (4.7%) 3 (3.6%) 7 (9.5%) 0 
Epilepsy/seizures 4 (1.8%) 0 3 (4.0%) 1 (1.8%) 
Head trauma with LOC 5 (2.3%) 1 (1.1%) 2 (2.7%) 2 (3.5%) 
Autoimmune disease 8 (3.6%) 5 (5.6%) 1 (1.3%) 2 (3.5%) 
Chronic alcohol abuse 11 (5.0%) 6 (6.7%) 5 (6.7%) 0 
Drug abuse 2 (0.9%) 0 2 (2.7%) 0 
Psychiatric history 
Treated for depression 50 (22.6%) 21 (23.6%) 17 (22.7%) 12 (21.1%) 
ECT 7 (3.2%) 5 (5.6%) 1 (1.3%) 1 (1.8%) 
Drug treatment 42 (19.0%) 16 (18.0%) 16 (21.3%) 10 (17.5%) 
Therapy/counseling 19 (8.7%) 8 (9.1%) 6 (8.0%) 5 (8.9%) 
LOC, loss of consciousness; ECT, electroconvulsive treatment. 
rated as reflecting at least mild atrophy. More notable atrophy was noted in 
patients from the CU study population (Table 6). 
At least one white matter lesion or lacune was noted in 55% of the patients. 
The distribution of lesions was similar across study sites. The distribution of 
frontal caps was similar across sites, but there was a significant difference in the 
frequency of parietal caps. The distribution of halos was also comparable across 
sites. 
EEG Studies 
One hundred thirty-six patients (65. 7%) had an EEG study as part of their 
diagnostic evaluation. EEG findings for these patients are shown in Table 7. The 
distribution of slowing was comparable across sites. 
Predictive Signs 
EPS 
Across all three sites, five patients had extrapyramidal signs that were judged 
to be definitely related. to current medications; in nine others, EPS might have 
resulted in part from medication use. These 14 patients were excluded from 
analysis of EPS. 
Overall, 40.2% of the study patients had at least one EPS sign rated as at least 
slight. The distribution of these patients varied significantly across sites, with 
more EPS noted at JH (52.6%) and MGH (50.9%) than at CU (23.1%). Using 
a more restrictive criterion for the presence of EPS requiring at least one sign 
rated at the mild-moderate range, 15.2% of patients overall had EPS. The dis-
tribution across sites was still uneven, with more EPS at MGH (24.6%) and JH 
(18.4%) than at CU (6.6%). Figure 1 summarizes the percentage of patients at 
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TABLE 3. Primary presenting complaint of patient and/or informant to the examining 
neurologist 
Overall cu JH MGH 
Memory deficit 179 (81.0%) 75 (83.3%) 56 (75.7%) 48 (84.2%) 
Performance problem 14 (6.3%) 6 (6.7%) 4 (5.4%) 4 (7.0%) 
Language problem 8 (3.6%) 4 (4.4%) 3 (4.1%) 1 (1.8%) 
Disorientation 8 (3.6%) 0 6 (8.1%) 2 (3.5%) 
Personality change 5 (2.3%) 2 (2.2%) 1 (1.4%) 2 (3.5%) 
Depressed mood 3 (1.4%) 1 (1.1%) 2 (2.7%) 0 
Behavior change 3 (1.4%) 2 (2.2%) 1 (1.4%) 0 
Psychosis 1 (0.5%) 0 1 (1.4%) 0 
each site who were rated as either slight or mild-moderate for each EPS. Again, 
frequencies for individual signs differed across site for speech, masked facies, 
rigidity, posture, bradykinesia, and gait. 
Patients with EPS were older than those without EPS (mean age 75.4 and 
70.3, respectively). Duration of illness was comparable in the two groups, how-
ever. EPS were noted more often in older patients, and this accounts to some 
degree for different frequencies across sites. However, differences in frequency 
of EPS across sites were still noted in analyses that controlled for age. 
The frequency of EPS in the pAD patients in this study was higher than that 
seen in an age-matched group of healthy elderly individuals (Bell et al., 1992). 
Myoclonus 
Only three patients in the entire study cohort had myoclonus, two at JH and 
one at MOH. In all cases myoclonus occurred only during sleep. Two patients 
at JH were also diagnosed with tardive dyskinesia. 
Psychotic and Behavioral Symptoms 
Overall, 24.3% of the patients met criteria for having had a delusion in the 
past month. Most common were paranoid delusions. The frequency of delusions 
was comparable across study sites. The frequency of hallucinations and illusions 
TABLE 4. Frequency of abnormalities noted on the neurological examination 
Overall CU JH MGH 
Consciousness 0 0 0 0 
Speech/language 21 (9.5%) 8 (8.8%) 13 (17.6%) 0 
Visual fields 4 (1.8%) 2 (2.2%) 2 (2.7%) 0 
Eye movements 5 (2.3%) 5 (5.6%) 0 0 
Other cranial nerves 9 (4.1%) 3 (3.3%) 5 (6.7%) 1 (1.8%) 
Motor 9 (4.1%) 4 (4.4%) 3 (4.0%) 2 (3.5%) 
Sensory 10 (4.5%) 7 (7.8%) 2 (2.7%) 1 (1.8%) 
Cerebellar 9 (4.1%) 6 (6.7%) 3 (4.0%) 0 
Movements 5 (2.3%) 4 (4.4%) 1 (1.3%) 0 
Reflexes 32 (14.4%) 12 (13.3%) 17 (22.7%) 3 (5.3%) 
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TABLE 5. Summary of standard and experimental medications currently prescribed 
Antidepressant 
Sedative/hypnotics 
Thyroid medication 
Research medications 
Combined CU JH MGH 
22 (9.6%) 
12 (5.3%) 
7 (3.1%) 
20 (8.9%) 
8 (8.8%) 
8 (8.8%) 
1 (1.1%) 
7 (7.7%) 
9 (11.8%) 
3 (3.9%) 
1 (1.3%) 
8 (10.5%) 
5 (9.0%) 
1 (1.8%) 
5 (8.8%) 
2 (3.6%) 
is summarized in Table 8. These were less frequent than delusions and their 
distribution also did not differ significantly across study sites. 
Other behavioral problems were frequent, occurring in 52.3% of the cohort. 
The frequency of these problems differed significantly across the three sites. 
Based on the CUSPAD, depressed mood (minimal to severe in intensity) was 
reported in 42.3% of the patients. There was a significant difference in severity 
of depressive symptoms across sites, with greater severity noted at CU. Similarly, 
Hamilton Depression Scale scores differed significantly across sites, with higher 
scores noted at CU. 
Disease Severity Descriptors 
General Severity Descriptors 
A review of general disease severity descriptors (Table 9) indicates that the 
cohort was early in the course of pAD and only mildly demented. 
Mean duration of illness, as estimated by the examining physician, was 4 
years, and did not differ significantly across sites. As estimated by the onset 
interview, mean duration was 4.26 years, slightly higher, and did not differ 
TABLE 6. Standardized ratings of features of CT and MRI scans by a single 
neuroradiologist 
Combined cu JH MGH 
MRI (n) 55 26 28 1 
CT (n) 103 32 27 44 
Atrophy 
none 17 (10.8%) 0 9 (16.4%) 8 (17.8%) 
mild 115 (72.8%) 43 (74.1%) 37 (67.3%) 35 (77.8%) 
moderate 25 (15.8%) 14 (24.1%) 9 (16.4%) 2 (4.4%) 
marked 1 (0.6%) 1 (1.7%) 0 0 
Lesions 
none 70 (44.3%) 27 (46.6%) 25 (45.5%) 18 (40.0%) 
single 34 (21.5%) 12 (20.7%) 12 (21.8%) 10 (22.2%) 
few 35 (22.2%) 11 (19.0%) 9 (16.4%) 15 (33.3%) 
multiple 18 (11.4%) 8 (13.8%) 8 (14.5%) 2 (4.4%) 
diffuse 1 (0.6%) 0 1 (1.8%) 0 
Caps 
frontal 42 (26.6%) 11 (19.0%) 19 (34.5%) 12 (26.7%) 
parietal 55 (34.8%) 20 (34.4%) 25 (45.4%) 10 (22.2%) 
Halo (in MR only) 22 (38.6%) 8 (30.7%) 13 (44.8%) 1 (50.0%) 
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TABLE 7. Features of EEG 
Combined CU JH MGH 
Had EEG 140 (62.8%) 64 (70.3%) 52 (69.3%) 24 (42.1%) 
Slow dominant rhythm 45 (32.4%) 24 (37.5%) 14 (27.5%) 7 (29.2%) 
Focal slowing 18 (13.0%) 8 (12.7%) 10 (19.6%) 0 
Intermittent rhythmic 
slowing 8 (5.8%) 3 (4.7%) 5 (10.0%) 0 
Focal epileptiform 3 (2.2%) 1 (1.6%) 2 (4.0%) 0 
Seizure 3 (1.3%) 0 2 (2.7%) 1 (1.8%) 
significantly across sites (p < 0.07). Mean CDR was 1.1, reflecting the fact that 
the great majority of patients (89.7%) were rated as having a CDR of 1, mild 
dementia. The remainder were rated as CDR 2. Distribution of CDR ratings did 
not differ significantly across sites. 
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FIG. 1. Percentage of patients 
at each study site rated as having 
specific extrapyramidal signs. 
Top: Signs rated at "slight" se-
verity or higher. Bottom: Signs 
rated at "mild-moderate" sever-
ity or higher. Hatched bars rep-
resent CU patients; gray bars 
represent JH patients; black bars 
represent MGH patients. 
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TABLE 8. Current psychiatric status as assessed by the CUSPAD and the Hamilton 
Depression Scale 
Any delusion 
Paranoid delusion 
Delusion of abandonment 
Somatic delusion 
Misidentification 
Other delusion 
Hallucinations 
Vague 
Clear 
Illusions 
Behavioral problems 
Depressed mood 
Hamilton Depression Scale 
Combined 
54 (24.3%) 
32 (14.4%) 
3 (1.4%) 
3 (1.4%) 
0 
4 (1.8%) 
7 (3.2%) 
11 (5.0%) 
7 (3.2%) 
116 (52.3%) 
94 (42.3%) 
3.22 (4.06) 
- cu 
22 (24.4%) 
14 (15.6%) 
1 (1.1%) 
2 (2.2%) 
0 
2 (2.2%) 
3 (3.3%) 
2 (2.2%) 
55 (61.1%) 
43 (47.8%) 
5.26 (4.80) 
JH MGH 
20 (26.7%) 12 (21.1%) 
11 (14.7%) 7 (12.3%) 
0 2 (3.5%) 
0 1 (1.8%) 
3 (4.0%) 1 (1.8%) 
4 (5.3%) 1 (1.8%) 
3 (4.0%) 5 (8.8%) 
4 (5.3%) 1 (1.8%) 
40 (53.3%) 21 (36.8%) 
29 (38.7%) 22 (38.6%) 
2.68 (3.56) 1.89 (3.04) 
Another approach to disease severity is to assess patients' living situation. 
Only 15 patients ( 6. 7%) were living in a nursing home. This reflects recruitment 
at MGH, where 14 patients were recruited from a chronic long-term care facility. 
Of those not living in a clinical facility, the majority (64.4%) were living at 
home, with their spouse, partner, children, family, or friends. Notably, 33 (17 .3%) 
were living alone at the time of first assessment. 
Even if patients are living at home, they may receive the equivalent of nursing 
home care. The "equivalent" care is assessed by Part 2 of the dependence scale. 
Based on interviewers' impressions, 55.6% of the patients had the equivalence 
of limited home care whereas 35.9% received the equivalent of custodial care. 
Only 19, including the 15 actually in a nursing home, were judged to be receiving 
the equivalent of care in a skilled nursing facility. 
TABLE 9. Indicators of severity of Alzheimer disease 
Combined cu JH MGH 
CDR 
Mean 1.10 (0.30) 1.11 (0.31) 1.12 (0.32) 1.07 (0.26) 
Mild (CDR = 1) 201 (89.7%) 81 (89.0%) 67 (88.2%) 53 (93.0%) 
Moderate (CDR = 2) 23 (10.3%) 10 (11.0%) 9 (11.8%) 4 (7.0%) 
Mean estimated duration 
Neurologist 3.98 (2.60) 3.36 (1.84) 4.72 (3.09) 4.00 (2.72) 
Onset interview 4.26 (3.47) 3.62 (2.58) 4.75 (4.16) 4.67 (3.64) 
Living status 
Alone 35 (16.8%) 17 (18.7%) 12 (16.0%) 6 (14.3%) 
With spouse at home 133 (63.9%) 56 (61.5%) 44 (58.7%) 33 (78.6%) 
With family at home 204 (91.1%) 91 (100.0%) 72 (94.7%) 41 (71.9%) 
Retirement home 3 (1.3%) 0 1 (1.3%) 2 (3.5%) 
Nursing home 15 (6.7%) 0 1 (1.3%) 14 (24.6%) 
Estimated equivalent care 
Limited home care 124 (55.6%) 38 (41.8%) 53 (70.7%) 33 (57.9%) 
Custodial care 80 (35.9%) 48 (52.7%) 22 (29.3%) 10 (17.5%) 
Skilled nursing facility 19 (8.5%) 5 (5.5%) 0 14 (24.6%) 
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TABLE 10. Mean scores on the modified Mini-Mental State Examination and its 
component subtests 
Maximum 
score Combined cu JH MGH 
Total 57 37.74 (5.55) 37.69 (5.20) 36.82 (5.40) 39.05 (6.1) 
Orientation 10 6.19 (2.21) 6.21 (2.20) 6.14 (2.06) 6.23 (2.4) 
Registration 3 2.82 (0.52) 2.78 (0.57) 2.79 (0.57) 2.93 (0.3) 
Digit span total 10 9.46 (1.87) 9.24 (1.65) 9.50 (2.18) 9.75 (1.7) 
Forward 6 5.80 (1.10) 5.66 (1.04) 5.95 (1.23) 5.82 (1.0) 
Backward 4 3.69 (0.98) 3.58 (0.97) 3.63 (0.99) 3.93 (0.9) 
Attention/calculation 7 3.29 (2.42) 3.09 (2.45) 3.03 (2.42) 3.95 (2.2) 
Presidents 5 1.46 (1.28) 1.81 (1.41) 1.25 (1.16) 1.18 (1.0) 
Recall 3 0.45 (0.74) 0.34 (0.70) 0.34 (0.62) 0.75 (0.8) 
Naming 10 7.77 (1.93) 7.84 (2.08) 7.87 (1.61) 7.53 (2.0) 
Language 7 5.94 (1.10) 6.04 (1.05) 5.66 (1.09) 6.14 (1.1) 
Construction 2 0.88 (0.78) 0.69 (0.76) 0.95 (0.80) 1.10 (0.7) 
Modified Mini-Mental State Examination 
Mean mMMSE score, along with means for each subscore are shown in Table 
10. Since no patients with a mMMSE score below 30 were entered into the 
study, the distribution of the total score was significantly positively skewed (z 
= 1.44, p = 0.032). These scores did not differ significantly across study sites. 
Blessed Dementia Rating Scale and Dependence Scale 
Mean total score for the Blessed Dementia Rating Scale (Part I) was 8.08. 
Overall, Blessed scores were higher at the CU site (Table 11). Item scores were 
also subdivided based on a factor analysis described previously. Scores on the 
cognitive factor, comprising the first seven test items suggested some difficulty 
with orientation, calculation, and chores. In contrast, scores were generally low 
(indicating preserved function) for the Basic Self-Care factor, which assesses 
eating, dressing, and toileting, again indicative of relatively mild dementia. Scores 
for the two personality change factors indicate the presence of both positive and 
negative personality changes. 
The mean dependence level indicates the ,need for help on only the earlier 
items on the dependence scale, such as requiring reminder to manage chores, or 
TABLE 11. Functional status and dependence, rated with the Blessed Dementia 
Rating Scale (Part 1) and the Dependence Scale 
Mean BDRS score 
BDRS factor scores 
Cognitive 
Personality 
Apathy 
Basic Self Care 
Dependence level 
Combined CU JH 
8.08 (3.47) 8.62 (3.58) 7.76 (3.62) 
3.03 (1.32) 
2.04 (1.64) 
1.74 (0.97) 
0.53 (0.90) 
2.23 (0.78) 
2.81 (1.16) 
2.44 (1.62) 
1.89 (0.96) 
0.64 (1.04) 
2.31 (0.74) 
3.19 (1.28) 
1.78 (1.62) 
1.50 (1.05) 
0.51 (0.85) 
2.13 (0.86) 
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MGH 
7.62 (3.00) 
3.16 (1.56) 
1.75 (1.61) 
1.82 (0.83) 
0.37 (0.67) 
2.26 (0.71) 
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needing to be watched or kept company when awake. Dependence levels did not 
differ significantly across sites. 
DISCUSSION 
Achieving the goal of developing a predictor model for the course of Alzheimer 
disease is dependent on developing a cohort with mild disease severity that is of 
sufficient size and is representative of patients typically diagnosed with pAD. The 
clinical diagnosis, staging of severity, and evaluation of potential components in the 
predictor model must be thorough and standardized, but optimally should use methods 
that could be reasonably applied in any clinical setting. The present report outlines 
our methodology toward meeting these goals. In order to achieve adequate statistical 
power, as well as to increase the generalizability of our findings, patients have been 
recruited from three different medical centers. These were representative of patients 
seen at medical centers specializing in AD. Utilization of multiple study sites de-
creases the chance that a resulting predictor model would be applicable only to a 
particular site, with idiosyncratic diagnostic or evaluation procedures. Although the 
investigators at each site are adept at applying diagnostic criteria for pAD, their 
available subject pool as well as their techniques for operationalizing diagnostic 
criteria differ to some degree. Also, referral issues at each site may differ because 
the CU site is primarily identified as a neurology department, JH as a psychiatry 
department, and MGH as a geriatric neurobehavioral center. Most importantly, our 
intended goal of developing a predictor model is dependent on identifying factors 
that account for differences in the rate of progression within the study cohort patients, 
so the cohort serves as its own control. 
Differences in potential subject pools across sites may be partially responsible 
for the variability seen across sites in some measures. However, the compatibility 
of most indices across sites is notable. Of primary importance is that in all cases 
patients met standard criteria for pAD as well as study criteria designed to ensure 
that patients were of mild disease severity. 
We were particularly concerned about the possibility that some study measures 
might be applied inconsistently. The most notable candidate in this regard is the 
assessment of extrapyramidal signs, since this requires a large degree of clinical 
judgment. A concurrent study performed at CU found good interrater reliability 
among three neurologists (Richards et al., 1991). However, these individuals 
were colleagues who trained and worked together. In order to maximize reliability 
of BPS ratings, several training and intersite reliability trials were conducted. 
These include visits of other sites' raters to CU as well as visits from CU to the 
two other sites. Formal estimates of interrater reliability for raters from the three 
sites was good. Despite these efforts, the frequency of BPS was higher at the JH 
and MGH sites than at CU. Some of this disparity is due to age differences across 
sites, particularly at MGH. It is notable that MGH reported higher frequencies 
of BPS whereas our reliability trials demonstrated a slight tendency for under-
rating signs at that site. Although some systematic overrating of BPS may exist, 
we are satisfied that on the whole, these differences in ratings represent actual 
differences in the frequency of BPS across sites. To the extent that intersite 
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variability does exist, larger effect sizes would be required to find predictive 
utility for BPS. 
Several new measures were developed specifically for the present study. The 
CUSP AD was developed as a brief, reliable assessment of psychopathology in 
pAD (Devanand et al., 1992). Although other scales for assessing psychopath-
ology in AD exist, none fully met our study design requirements. We required 
a short instrument that could be administered by a lay interviewer with little 
formal training. To that end, the CUSP AD utilizes explicit questions that scan 
the spectrum of psychopathology that commonly occurs in AD in order to de-
termine the presence or absence of specific symptoms. 
The dependence scale was also developed to meet the specific need for a 
severity measure or outcome that captures the amount of aid a patient is receiving, 
no matter what their living situation (Stern et al., 1992). A portion of patients 
included in the MGH cohort reside in a long-term care facility, but still meet all 
study inclusion and exclusion criteria. This suggests that nursing home entry per 
se is not a useful outcome for prediction, because even patients with mild disease 
may be institutionalized. The dependence scale investigates the actual amount of 
care a patient requires and is less liable to be influenced by sociological or 
financial factors that contribute to the decision to institutionalize a patient. 
We chose to include patients with small subcortical lesions but without history 
or clinical evidence of stroke in our group with pAD. To the extent that these 
lesions contribute to the presentation of dementia, some might feel that these 
patients would better be diagnosed with possible AD according to NINCDS-
ADRDA criteria. However, the influence of the lesions on clinical presentation 
or disease course is an empirical issue that can be tested with the present cohort. 
Our preliminary evidence suggests that there is no difference between patients 
with and without these lesions at their initial presentation (Marder et al., 1992), 
but these findings must be confirmed and prospective data are required. 
We also chose to include patients who were participating in experimental drug 
trials. Pragmatically, we felt that few patients with mild AD would consent to 
participate in the present study if it meant restricting access to therapeutic trials. 
Similarly, ethical considerations would dictate against such an exclusion crite-
rion. From a design point of view, the potential effects of participation in these 
trials was considered a tolerable source of potential variation. Although some 
therapeutic trials have resulted in statistically significant improvements on cri-
terion measures, the clinical significance of this improvement has been difficult 
to establish and is at best small. However, subjects' participation in these trials 
is carefully recorded so that potential drug effects on progression can be assessed 
or analyses can stratify by participation in these studies. 
By standard measures such as the mMMSB, BDRS, duration of illness, and 
CDR, the cohort consisted of patients in the early stages of disease. For example, 
the average mMMSB score of the cohort is roughly equivalent to a score of 20 
on the standard Mini-Mental. Still, BPS and behavioral disturbances were rela-
tively common. This observation lends credence to their use as predictive signs: 
They are not simply signs of more advanced disease and occur early enough to 
be of potential value for predicting disease course. 
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